EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Douillard, Jean-Yves [1 ]
Ostoros, Gyula [2 ]
Cobo, Manuel [3 ]
Ciuleanu, Tudor [4 ]
Mccormack, Rose [7 ]
Webster, Alan [5 ]
Milenkova, Tsveta [6 ]
机构：
[1] Ico R Gauducheau, St Herblain, France
[2] Koranyi Natl Inst Tb & Pulmonol, Budapest, Hungary
[3] Hru Carlos Haya, Malaga, Spain
[4] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania
[5] Astrazeneca, Biometr & Informat Sci, Cambridge, England
[6] Astrazeneca, Res & Dev, Cambridge, England
[7] Astrazeneca, Personalised Healthcare, Luton, Beds, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR mutation; gefitinib; NSCLC; Caucasian; circulating-free DNA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-020
引用
收藏
页码：S1194 / S1195
页数：2
相关论文
共 50 条
  • [1] PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): POST-HOC EXPLORATORY ANALYSES OF EGFR MUTATIONS IN PLASMA-DERIVED CFDNA SAMPLES
    Douillard, Jean-Yves
    Ostoros, Gyula
    Cobo, Manuel
    Ciuleanu, Tudor
    Mccormack, Rose
    Webster, Alan
    Milenkova, Tsveta
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S899 - S900
  • [2] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    Douillard, J-Y
    Ostoros, G.
    Cobo, M.
    Ciuleanu, T.
    McCormack, R.
    Webster, A.
    Milenkova, T.
    BRITISH JOURNAL OF CANCER, 2014, 110 (01) : 55 - 62
  • [3] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
    J-Y Douillard
    G Ostoros
    M Cobo
    T Ciuleanu
    R McCormack
    A Webster
    T Milenkova
    British Journal of Cancer, 2014, 110 : 55 - 62
  • [4] Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
    Lim, Sung Won
    Park, Sehhoon
    Kim, Youjin
    Cho, Jang Ho
    Park, Song Ee
    Lee, Hansang
    Kim, Hee Kyung
    Kim, Sung Min
    Sun, Jong Mu
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    LUNG CANCER, 2018, 124 : 293 - 297
  • [5] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [6] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)
    Goto, Koichi
    Nishio, Makoto
    Yamamoto, Noboru
    Chikamori, Kenichi
    Hida, Toyoaki
    Maemondo, Makoto
    Katakami, Nobuyuki
    Kozuki, Toshiyuki
    Yoshioka, Hiroshige
    Seto, Takashi
    Fukuyama, Tamaki
    Tamura, Tomohide
    LUNG CANCER, 2013, 82 (01) : 109 - 114
  • [7] Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study
    Abdullah, Matin Mellor
    Bhat, Amit
    Mohamed, Ahmad Kamal
    Ching, Foo Yoke
    Ahmed, Nida
    Gantotti, Sandeep
    ONCOLOGY LETTERS, 2016, 11 (04) : 2757 - 2762
  • [8] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [9] Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence
    Gridelli, C.
    De Marinis, F.
    Di Maio, M.
    Cortinovis, D.
    Cappuzzo, F.
    Mok, T.
    LUNG CANCER, 2011, 71 (03) : 249 - 257
  • [10] Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
    Mok, Tony S. K.
    Kim, Sang-We
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Yang, Jin-Ji
    Ahn, Myung-Ju
    Wang, Jie
    Yang, James Chih-Hsin
    Lu, You
    Atagi, Shinji
    Ponce, Santiago
    Shi, Xiaojin
    Rukazenkov, Yuri
    Haddad, Vincent
    Thress, Kenneth S.
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 4027 - +
12345